Antianginal and antiischemic efficacy of conventional and slow-release form
s of isosorbide-5-mononitrate was confirmed in a study on patients with sta
ble class II-III effort angina and reproducible myocardial ischemia. Differ
ences in kinetic characteristics of these 2 drug forms allowed to individua
lize treatment of patients and to lower risk of development of nitrate tole
rance.